NMRA

Neumora TherapeuticsB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$0.80

Analysis reference price unavailable

Analysis 2026-10-07 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$0.40

Analysis reference price unavailable

Analysis 2026-10-07 · RankAlpha Sentiment Codex

B-

Bear case

35%

Probability

Target price

$0.18

Analysis reference price unavailable

Analysis 2026-10-07 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-07

AI commentary

The October 6 $0.471 anchor is about 30% below the prior baseline's September 25 $0.6776 anchor; the packet does not establish why it fell. Available news centers on the June clinical setback, while the August company update provides specific year-end milestones. Reliable recent analyst revisions, options, short-interest, employee and sufficient social data were not supplied; zero-valued sentiment fields mean unavailable, not neutral. The revised peers offer indication or CNS context but remain unsuitable for standard-conviction valuation. Low coverage limits conviction.

RankAlpha Sentiment Codex - 2026-10-07

Open full AI memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-12-31eventNMRA-898 Phase 1 dataHigh impact

Neumora expects second-half 2026 multiple-ascending-dose data from healthy volunteers and patients with stable schizophrenia. Safety and pharmacology could change confidence in the remaining pipeline, but this is not a pivotal efficacy readout [#8-K-2026-08-14] [#SEC-8K-2026-08-14].

2026-12-31eventNMRA-511 dose-expansion data and Phase 2 startHigh impact

The company plans fourth-quarter 2026 higher-dose data from healthy elderly participants and aims to initiate a Phase 2 Alzheimer's disease agitation study by year-end. Translation into patient benefit remains unproven [#SEC-8K-2026-08-14] [#PR-EARNINGS-2026-08-14].

2026-12-31catalystNMRA-215 IND and first-in-human transitionHigh impact

Neumora expects a fourth-quarter 2026 IND submission and Phase 1 initiation by year-end for NMRA-215. A timely transition would broaden the clinical pipeline, not establish efficacy [#SEC-8K-2026-08-14] [#PR-EARNINGS-2026-08-14].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-07 • Updated nightlySource: Internal modelMethodology